PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

PainReform Ltd. (Nasdaq: PRFX), a clinical stage specialty pharmaceutical company, announced participation in the H.C. Wainwright BioConnect 2021 Conference, occurring virtually from January 11-14, 2021. A webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 a.m. ET, accessible for 90 days. PainReform's lead product, PRF-110, aims to enhance post-operative pain relief using a proprietary extended-release drug-delivery system, targeting the local anesthetic market with reduced opiate needs.

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

A webcast of PainReform's presentation will be available on-demand as of 6:00 a.m. ET, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of PainReform's website at www.painreform.com/investors-information/.

About PainReform

PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

FAQ

When is PainReform presenting at the H.C. Wainwright BioConnect 2021 Conference?

PainReform will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021.

How can I access PainReform's webcast from the conference?

The webcast will be available on-demand starting January 11, 2021, at 6:00 a.m. ET for 90 days.

What is PainReform's lead product?

PainReform's lead product is PRF-110, which focuses on post-operative pain relief using local anesthetic ropivacaine.

What is the purpose of PRF-110?

PRF-110 is designed to provide localized and extended post-operative analgesia directly into the surgical wound bed.

How does PainReform's drug-delivery system work?

The proprietary system delivers extended pain relief without repeated doses, minimizing the need for opiates.